Deerland Enzymes & Probiotics, a Kennesaw, Georgia-based developer, formulator, and manufacturer of enzyme- and probiotic-based dietary supplements, received an investment from RoundTable Healthcare Partners.
The financial terms of the transaction were not disclosed.
Led by Chief Executive Officer, Scott Ravech, Deerland Enzymes & Probiotics specializes in customized enzyme and probiotic-based formulations, collaborating with customers to develop innovative and often proprietary solutions. In addition to customized formulations, the company offers a line of university and clinically studied branded products.
Deerland provides regulatory support and performs specialty contract manufacturing services, including bulk blends, liquids, hard shell capsules, and tablets, as well as bottling and labeling.
Deerland is the fourth investment from RoundTable’s $650m Fund IV. As part of the transaction and to finance further growth opportunities for the company, RoundTable facilitated the completion of new senior credit facilities and a private placement of senior subordinated notes. The senior credit facilities were led by Capital One Healthcare and included The PrivateBank, while the senior subordinated notes were provided by RoundTable Capital Partners III, RoundTable’s third captive subordinated debt fund.